Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan
Multiple myeloma (MM) is a hematologic malignancy characterized by monoclonal proliferation of plasma cells that leads to bone disease, including lytic lesions and osteoporosis [...].
Authors
- Kazuhito Suzuki (ORCID: https://orcid.org/0000-0002-0300-378X)
- Yosuke Koroki (ORCID: https://orcid.org/0000-0003-1461-5869)
- Hiroaki Tsuchiya (ORCID: https://orcid.org/0000-0001-6530-7298)
- Yuma Fujimori
- Chika Sakai (ORCID: https://orcid.org/0000-0003-3686-6669)
Institutions
- Jikei University School of Medicine (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-22
- DOI
- https://doi.org/10.3390/cancers17091389
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Johnson and Johnson